

## Claims

1. A combined preparation for simultaneous, separate or  
5 sequential use as a contrast agent in ultrasound  
imaging, said preparation comprising:  
i) an injectable aqueous medium having gas dispersed  
therein; and  
ii) a composition comprising a diffusible component  
10 capable of diffusion in vivo into said dispersed  
gas so as at least transiently to increase the  
size thereof.
2. A combined preparation as claimed in claim 1 wherein  
15 the dispersed gas comprises air, nitrogen, oxygen,  
carbon dioxide, hydrogen, an inert gas, a sulphur  
fluoride, selenium hexafluoride, an optionally  
halogenated silane, a low molecular weight  
hydrocarbon, a ketone, an ester, a halogenated low  
20 molecular weight hydrocarbon or a mixture of any of  
the foregoing.
3. A combined preparation as claimed in claim 2 wherein  
the gas comprises a perfluorinated ketone,  
25 perfluorinated ether or perfluorocarbon.
4. A combined preparation as claimed in claim 3 wherein  
the perfluorocarbon comprises a perfluoroalkane,  
perfluoroalkene or perfluorocycloalkane.  
30
5. A combined preparation as claimed in claim 2 wherein  
the gas comprises sulphur hexafluoride or a

perfluoropropane, perfluorobutane or perfluoropentane.

- 5 6. A combined preparation as claimed in any of the preceding claims wherein the dispersed gas is stabilised by a coalescence-resistant surface membrane, a filmogenic protein, a polymer material, a non-polymeric and non-polymerisable wall-forming material or a surfactant.
- 10 7. A combined preparation as claimed in claim 6 wherein said surfactant comprises at least one phospholipid.
- 15 8. A combined preparation as claimed in claim 7 wherein at least 75% of the said surfactant material comprises phospholipid molecules individually bearing net overall charge.
- 20 9. A combined preparation as claimed in claim 8 wherein at least 75% of the film-forming surfactant material comprises one or more phospholipids selected from phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins.
- 25 10. A combined preparation as claimed in claim 9 wherein at least 80% of said phospholipids comprise phosphatidylserines.
- 30 11. A combined preparation as claimed in any of the preceding claims wherein the composition comprising the diffusible component is formulated for administration cutaneously, subcutaneously,

intramuscularly, intravenously or by inhalation.

12. A combined preparation as claimed in any of claims 1  
to 10 wherein the composition comprising the  
5 diffusible component further comprises a carrier  
liquid.
13. A combined preparation as claimed in claim 12 wherein  
the diffusible component is dispersed in an aqueous  
10 carrier liquid in the form of an oil-in-water emulsion  
or microemulsion.
14. A combined preparation as claimed in claim 13 wherein  
the diffusible component comprises an aliphatic ether,  
15 polycyclic oil, polycyclic alcohol, heterocyclic  
compound, aliphatic hydrocarbon, cycloaliphatic  
hydrocarbon or halogenated low molecular weight  
hydrocarbon.
- 20 15. A combined preparation as claimed in claim 14 wherein  
the diffusible component comprises a perfluorocarbon.
16. A combined preparation as claimed in claim 15 wherein  
the perfluorocarbon comprises a perfluoroalkane,  
25 perfluoroalkene, perfluorocycloalkane,  
perfluorocycloalkene or perfluorinated alcohol.
17. A combined preparation as claimed in claim 16 wherein  
the diffusible component comprises perfluoropentane,  
30 perfluorohexane or perfluorodimethylcyclobutane.
18. A combined preparation as claimed in any of claims 13

to 17 wherein the emulsion is stabilised by a phospholipid surfactant.

- 5 19. A combined preparation as claimed in claim 18 wherein at least 75% of the said phospholipid surfactant comprises molecules individually bearing net overall charge.
- 10 20. A combined preparation as claimed in claim 19 wherein at least 75% of the phospholipid surfactant is selected from phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins.
- 15 21. A combined preparation as claimed in claim 20 wherein at least 80% of said phospholipid surfactant comprises phosphatidylserines.
- 20 22. A combined preparation as claimed in any of the preceding claims which further includes a vasodilator drug.
- 25 23. A combined preparation as claimed in claim 22 wherein said vasodilator drug is adenosine.
24. A combined preparation as claimed in any of claims 1 to 21 which further includes a therapeutic agent.
- 30 25. A combined preparation as claimed in any of claims 1 to 21 which further includes contrast-enhancing moieties for an imaging modality other than ultrasound.

- 10007325 120501
26. A method of generating enhanced images of a human or non-human animal subject which comprises the steps of:
- 5 i) injecting a physiologically acceptable aqueous medium having gas dispersed therein into the vascular system of said subject;
- 10 ii) before, during or after injection of said aqueous medium administering to said subject a composition comprising a diffusible component capable of diffusion *in vivo* into said dispersed gas so as at least transiently to increase the size thereof; and
- 15 iii) generating an ultrasound image of at least a part of said subject.
27. A method as claimed in claim 26 wherein the composition comprising the diffusible component is administered cutaneously, subcutaneously, intramuscularly, intravenously or by inhalation.
- 20 28. A method as claimed in claim 26 or claim 27 wherein a vasodilator drug is coadministered to the subject.
- 25 29. A method as claimed in claim 28 wherein said vasodilator drug is adenosine.